IHI — iShares U.S. Medical Devices ETF
Healthcare Ranked #443 of 458 tracked ETFs · Issued by iShares
IHI Price Performance — Growth of $10,000
Value of a $10,000 investment in IHI over time, compared with SPY. Both lines are rebased to $10,000 on the first shared date. Based on total returns — prices are adjusted for dividends and splits, so this assumes distributions were reinvested. Hover or tap the chart for exact values.
IHI Drawdown
The "underwater" chart: IHI's decline from its highest prior value at each point in time. It shows how deep past losses ran and how long the fund took to recover to break-even.
What If You'd Invested in IHI?
See what a lump sum in IHI would have grown to, with the option to add a regular monthly contribution on top. Figures use total returns — dividends are assumed reinvested.
Past performance doesn't predict future results. Assumes contributions on the first trading day of each month, no trading costs or taxes, and reinvested distributions. History is limited to the range published in the site's daily return data.
Overview
The iShares U.S. Medical Devices ETF (IHI) is a Healthcare sector fund issued by iShares with $3.02 billion in assets under management. Trading at a price of $50.23, the fund carries an expense ratio of 0.38% and offers a dividend yield of 0.49%. ETFValuer ranks this fund #443 out of 458 tracked ETFs across all categories, assigning it an overall grade of F with a score of 32.0 out of 100. Within the Healthcare category specifically, the fund is one of 11 ETFs monitored by the platform. The combination of a low grade and a rank near the bottom of the total universe suggests limited investor adoption relative to peers. Despite the substantial asset base, the fund's performance metrics and cost structure place it in the lower tier of the tracked landscape.
Recent price action shows a 1-day return of +1.60% and a 1-week decline of -0.55%, while the 1-month return stands at +1.23%. Over longer horizons, the fund has experienced significant negative momentum, with a 3-month return of -5.10% and a 6-month return of -17.17%. Year-to-date performance is -18.65%, and the 1-year return is -17.48%, indicating a sustained downward trend over the past year. The 3-year return is -9.16%, reflecting a prolonged period of underperformance relative to the start of the period. This pattern demonstrates a divergence where short-term fluctuations have not been enough to offset the substantial losses accumulated over the last six months to three years.
The fund is assigned a Moderate volatility label and has a beta of 0.82, suggesting it moves slightly less than the broader market on average. A Sharpe ratio of -1.15 indicates that the fund has generated negative risk-adjusted returns over the measured period. The maximum drawdown of -26.64% highlights the severity of the peak-to-trough decline experienced by investors. This combination of a negative Sharpe ratio and a deep maximum drawdown implies that the fund has struggled to provide compensation for the volatility it introduces. While the beta below 1.0 suggests slightly lower sensitivity to market swings, the negative returns and high drawdown have resulted in a poor risk-reward profile for the period analyzed.
AI-generated summary based on the data on this page.
IHI Top Holdings
| # | Holding | % of Net Assets | Value |
|---|---|---|---|
| 1 | ABBOTT LABORATORIES | 16.98% | $539M |
| 2 | INTUITIVE SURGICAL, INC. | 15.57% | $494M |
| 3 | STRYKER CORPORATION | 10.76% | $342M |
| 4 | MEDTRONIC PUBLIC LIMITED COMPANY | 4.62% | $147M |
| 5 | BECTON, DICKINSON AND COMPANY | 4.57% | $145M |
| 6 | EDWARDS LIFESCIENCES CORPORATION | 4.47% | $142M |
| 7 | IDEXX LABORATORIES, INC. | 4.44% | $141M |
| 8 | RESMED INC. | 4.43% | $141M |
| 9 | GE HEALTHCARE TECHNOLOGIES INC. | 4.40% | $140M |
| 10 | BOSTON SCIENTIFIC CORPORATION | 4.28% | $136M |
Holdings as of 2026-03-31 per the fund's most recent SEC N-PORT-P filing. Top 10 holdings make up 74.5% of net assets — a rough gauge of concentration risk (the higher this figure, the more the fund's return depends on a handful of names). To see how IHI's holdings overlap with other ETFs you own or are considering, check the Stock Overlap tool.
Which Funds Overlap With IHI
Holding two funds that own the same companies adds cost and complexity without adding much diversification. These tracked ETFs share the most names with IHI's top 10 — VHT overlaps most, holding 2 of the same companies as IHI's top 10 (32.5% of IHI's assets).
| ETF | Name | Shared Companies | IHI Weight | Examples |
|---|---|---|---|---|
| VHT | Vanguard Health Care Index Fund ETF Shares | 2 | 32.5% | ABBOTT LABORATORIES, INTUITIVE SURGICAL, INC. |
| XLV | State Street Health Care Select Sector SPDR ETF | 2 | 32.5% | ABBOTT LABORATORIES, INTUITIVE SURGICAL, INC. |
| FHLC | Fidelity MSCI Health Care Index ETF | 2 | 32.5% | ABBOTT LABORATORIES, INTUITIVE SURGICAL, INC. |
| IYH | iShares U.S. Healthcare ETF | 2 | 32.5% | ABBOTT LABORATORIES, INTUITIVE SURGICAL, INC. |
| BOTZ | Global X Robotics & Artificial Intelligence ETF | 1 | 15.6% | INTUITIVE SURGICAL, INC. |
Compares the top 10 reported holdings of each fund, so it's a floor on true overlap — two S&P 500 trackers overlap ~100% even when only 10 names are listed. Use the Stock Overlap tool to search by individual company.
Market Backdrop
10-Year Treasury Yield: 4.71% (as of 2026-07-23) — The yield on 10-year US Treasury bonds — the standard "risk-free rate" benchmark used to contextualize this fund’s Sharpe ratio and returns.
CBOE Volatility Index (VIX): 18.70 (as of 2026-07-23) — A real-time gauge of expected S&P 500 volatility over the next 30 days — useful context for this fund’s own volatility label.
Federal Funds Rate: 3.63% (as of 2026-06-01) — The Federal Reserve’s target policy rate, which anchors short-term borrowing costs across the economy.
What IHI's Fees Cost You
IHI charges an expense ratio of 0.38% a year, deducted automatically from the fund's value. Small percentages compound into real money — adjust the figures below to see the impact on your own numbers.
Assumes a constant gross return and no additional contributions — a simplification, but it isolates exactly what the expense ratio costs. Try the full fee calculator to model contributions and compare any two funds.
IHI Dividend Income Estimator
IHI currently yields 0.49%. Enter an amount to see the income that implies, or set a monthly income target to see the investment it would take.
Based on the fund's current trailing yield, which varies with price and distributions — treat it as an estimate, not a guarantee. Yields are not adjusted for tax.
IHI Liquidity, Domicile & Tax Treatment
Liquidity: Quoted bid/ask spread is 0.38% and average daily volume is 2.9M/day. Tighter spreads and higher volume mean lower round-trip trading costs; this is a live-market snapshot and can widen during volatile sessions. AUM of $3.02B provides ample scale, supporting tight spreads and issuer commitment to keep the fund open.
Domicile & tax treatment: IHI is a US-domiciled, SEC-registered ('40 Act) exchange-traded fund. Dividends and capital gains distributions are reported to US investors on Form 1099-DIV, and the fund is not subject to the PFIC reporting or UCITS-specific rules that apply to Irish- or Luxembourg-domiciled funds. Non-US investors should note that US-domiciled ETFs are generally subject to 30% US withholding tax on dividends (unless reduced by treaty) and to US estate tax exposure on the position — Irish-domiciled UCITS ETFs tracking the same index often avoid both, which is why non-US residents frequently prefer the UCITS equivalent where one exists. This is general information, not tax advice — consult a tax professional for your situation.
IHI Performance History
| Period | Return |
|---|---|
| 1-Day | +1.60% |
| 1-Week | -0.55% |
| 1-Month | +1.23% |
| 3-Month | -5.10% |
| 6-Month | -17.17% |
| YTD | -18.65% |
| 1-Year | -17.48% |
| 3-Year | -9.16% |
How IHI Compares to Other Healthcare ETFs
| Rank | Grade | Ticker | Name | 1-Year | Exp. Ratio | AUM |
|---|---|---|---|---|---|---|
| #66 | B |
XBI | State Street SPDR S&P Biotech ETF | +71.35% | 0.35% | $10.7B |
| #69 | B |
VHT | Vanguard Health Care Index Fund ETF Shares | +23.45% | 0.09% | $20.4B |
| #92 | B |
XLV | State Street Health Care Select Sector SPDR ETF | +21.38% | 0.08% | $40.6B |
| #110 | B |
FHLC | Fidelity MSCI Health Care Index ETF | +23.55% | 0.084% | $3.22B |
| #122 | B |
XPH | State Street SPDR S&P Pharmaceuticals ETF | +57.67% | 0.35% | $428M |
| #125 | B |
IBB | iShares Biotechnology ETF | +39.29% | 0.44% | $9.09B |
| #172 | B |
PPH | VanEck Pharmaceutical ETF | +26.45% | 0.36% | $879M |
| #198 | C |
IYH | iShares U.S. Healthcare ETF | +21.01% | 0.38% | $3.16B |
| #293 | C |
IHF | iShares U.S. Healthcare Providers ETF | +30.54% | 0.38% | $1.18B |
| #389 | D |
ARKG | ARK Genomic Revolution ETF | +42.41% | 0.75% | $1.73B |
| #443 | F |
IHI | iShares U.S. Medical Devices ETF | -17.48% | 0.38% | $3.02B |